Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26227804 | 0.83 | PIK3CD (0.49) | PIK3CDMCHR1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL21106061 | 0.82 | MCHR1 (0.47) | PIK3CDMCHR1EPHX2NPY5RHSD17B10 | |
| SCHEMBL19275282 | 0.80 | EPHX2 (0.44) | EPHX2NPY5REPHX1ALDH1A1 | |
| SCHEMBL25883657 | 0.79 | POLB (0.46) | PIK3CDMCHR1HSD17B10KDM4EGAA | |
| SCHEMBL12516865 | 0.79 | L3MBTL3 (0.53) | EPHX2NPY5REPHX1ALDH1A1 | |
| SCHEMBL21787323 | 0.78 | PIK3CD (0.44) | PIK3CDMCHR1HSD17B10KDM4E | |
| SCHEMBL21281128 | 0.77 | EPHX2 (0.49) | EPHX2NPY5REPHX1ALDH1A1MEN1 | |
| SCHEMBL18909251 | 0.77 | EPHX2 (0.45) | EPHX2NPY5REPHX1ALDH1A1MEN1 | |
| SCHEMBL18909244 | 0.77 | EPHX2 (0.49) | EPHX2NPY5REPHX1ALDH1A1MEN1 | |
| SCHEMBL19419451 | 0.77 | NPY5R (0.44) | EPHX2NPY5RGAAEPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | PIK3CD 421/4885MCHR1 4631/4885EPHX2 3319/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885MCHR1 3799/4885EPHX2 1890/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885MCHR1 3799/4885EPHX2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.